Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DETECT II: DMEK vs DSO with Ripasudil for Fuchs Endothelial Dystrophy
NCT05275972Phase 3Recruiting
- Sponsor
- Stanford University
- Start
- Jan 2023
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ripasudil in Fuchs endothelial dystrophy (FED), sponsored by Stanford University. Started Jan 2023; status: recruiting.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT05275972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05275972.